Literature DB >> 34511812

Midodrine and the Ladder of Evidence to Climb.

Naaventhan Palaniyappan1,2, Guruprasad P Aithal1,2.   

Abstract

Entities:  

Keywords:  ACLF, Acute on chronic liver failure; PTFE, Polytetrafluoroethylene; SCO, Standard of care; TIPS, Transjugular portosystemic shunts

Year:  2021        PMID： 34511812      PMCID： PMC8414407          DOI： 10.1016/j.jceh.2021.07.002

Source DB:  PubMed          Journal:  J Clin Exp Hepatol        ISSN： 0973-6883


× No keyword cloud information.
  14 in total

1.  Satavaptan for the management of ascites in cirrhosis: efficacy and safety across the spectrum of ascites severity.

Authors:  Florence Wong; Hugh Watson; Alexander Gerbes; Hendrik Vilstrup; Salvatore Badalamenti; Mauro Bernardi; Pere Ginès
Journal:  Gut       Date:  2011-08-11       Impact factor: 23.059

2.  Decreasing mortality among patients hospitalized with cirrhosis in the United States from 2002 through 2010.

Authors:  Monica L Schmidt; A Sidney Barritt; Eric S Orman; Paul H Hayashi
Journal:  Gastroenterology       Date:  2015-01-23       Impact factor: 22.682

3.  Midodrine and clonidine in patients with cirrhosis and refractory or recurrent ascites: a randomized pilot study.

Authors:  Virendra Singh; Ajay Singh; Baljinder Singh; Rajesh Vijayvergiya; Navneet Sharma; Anchal Ghai; Ashish Bhalla
Journal:  Am J Gastroenterol       Date:  2013-02-19       Impact factor: 10.864

4.  The effects of chronic treatment with octreotide versus octreotide plus midodrine on systemic hemodynamics and renal hemodynamics and function in nonazotemic cirrhotic patients with ascites.

Authors:  Georgios Kalambokis; Michalis Economou; Andreas Fotopoulos; Jihad Al Bokharhii; Christos Pappas; Afroditi Katsaraki; Epameinondas V Tsianos
Journal:  Am J Gastroenterol       Date:  2005-04       Impact factor: 10.864

5.  Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome.

Authors:  Florence Wong; S Chris Pappas; Michael P Curry; K Rajender Reddy; Raymond A Rubin; Michael K Porayko; Stevan A Gonzalez; Khalid Mumtaz; Nicholas Lim; Douglas A Simonetto; Pratima Sharma; Arun J Sanyal; Marlyn J Mayo; R Todd Frederick; Shannon Escalante; Khurram Jamil
Journal:  N Engl J Med       Date:  2021-03-04       Impact factor: 91.245

6.  A Randomized Trial of Albumin Infusions in Hospitalized Patients with Cirrhosis.

Authors:  Louise China; Nick Freemantle; Ewan Forrest; Yiannis Kallis; Stephen D Ryder; Gavin Wright; Andrew J Portal; Natalia Becares Salles; Derek W Gilroy; Alastair O'Brien
Journal:  N Engl J Med       Date:  2021-03-04       Impact factor: 91.245

7.  Effects of a 7-day treatment with midodrine in non-azotemic cirrhotic patients with and without ascites.

Authors:  Georgios Kalambokis; Andreas Fotopoulos; Michalis Economou; Konstantinos Pappas; Epameinondas V Tsianos
Journal:  J Hepatol       Date:  2006-11-10       Impact factor: 25.083

8.  Clinical study on the therapeutic role of midodrine in non azotemic cirrhotic patients with tense ascites: a double-blind, placebo-controlled, randomized trial.

Authors:  Ahmed Ali; Samar Farid; Mona Amin; Mohamed Kassem; Nouman Al-Garem
Journal:  Hepatogastroenterology       Date:  2014-10

9.  Transjugular Intrahepatic Portosystemic Shunts With Covered Stents Increase Transplant-Free Survival of Patients With Cirrhosis and Recurrent Ascites.

Authors:  Christophe Bureau; Dominique Thabut; Frédéric Oberti; Sébastien Dharancy; Nicolas Carbonell; Antoine Bouvier; Philippe Mathurin; Philippe Otal; Pauline Cabarrou; Jean Marie Péron; Jean Pierre Vinel
Journal:  Gastroenterology       Date:  2016-09-20       Impact factor: 22.682

10.  Midodrine and tolvaptan in patients with cirrhosis and refractory or recurrent ascites: a randomised pilot study.

Authors:  Nitish Rai; Baljinder Singh; Akash Singh; Rajesh Vijayvergiya; Navneet Sharma; Ashish Bhalla; Virendra Singh
Journal:  Liver Int       Date:  2016-10-02       Impact factor: 5.828
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.